WILMINGTON, Del., Nov. 2 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:
AZN) is disappointed with today's ruling and we intend to appeal. We
believe the ruling is unsupported as the conduct at issue was the result of
highly competitive conditions in the pharmaceutical marketplace, which led
to discounting. The Court's prior ruling on liability is thus profoundly
anti- competitive.
AstraZeneca has competed responsibly with respect to pricing and
marketing of drugs and we firmly believe that we have acted at all times in
accordance with the law.
The plaintiffs are fully aware of AWP pricing and still use AWP as a
reimbursement benchmark today. The result of AstraZeneca's conduct in this
case was to keep a lower cost product competitive under the Government's
reimbursement system, thereby saving Medicare and patients millions of
dollars.
SOURCE AstraZeneca
 back to top
Related links:
http://www.astrazeneca-us.com/
http://www.prnewswire.com/comp/985887.html /
CONTACT:
Tony Jewell, +1-302-885-4594,
Tony.Jewell@AstraZeneca.com, or Laura Woodin, +1-302-885-1087,
Laura.Woodin@AstraZeneca.com, both of AstraZeneca
|
